Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide

A. Ladányi, Michael I. Nishimura, Steven A. Rosenberg, James C. Yang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The significance of CD4+ lymphocytes and major histocompatibility complex (MHC) class II-restricted antigens in antitumor immunity has been demonstrated in several animal models as well as in some human tumors. However, because of the lack of known class II-restricted antigens, the participation of CD4+ cells in antitumor responses has not been well characterized. Recent reports showed that class II proteins covalently linked to an antigenic peptide could be constructed and cells expressing these fusion proteins were recognized by specific T(H) cells. The aim of this study was to determine the effect of the expression of a class II-peptide construct on the tumorigenicity and immunogenicity of transfected murine tumor cells. We have constructed a gene for I-E(d) β chain covalently coupled to the I- E(d)-restricted T(H) cell determinant of sperm whale myoglobin (SWM132- 145). This class II fusion protein was recognized by a specific T(H) cell line on the surface of COS-7 cells or BALB/c sarcoma cells. The sarcoma cells expressing the MHC-peptide complex were rejected by immunocompetent BALB/c mice, and in vivo T-cell subset depletion experiments suggested the importance of CD4+ cells in the rejection. Moreover, splenocytes from mice immunized with tumor cells expressing the I-E(d)-SWM complex showed specific peptide recognition in vitro. Such covalent MHC-peptide complexes could prove useful in studies on the role of CD4+ lymphocytes in antitumor immune responses, and also in designing new, more effective vaccine approaches to the immunotherapy of cancer, as class II-restricted tumor-associated antigens are identified for human cancers.

Original languageEnglish
Pages (from-to)36-47
Number of pages12
JournalJournal of Immunotherapy
Volume23
Issue number1
DOIs
Publication statusPublished - 2000

Fingerprint

Major Histocompatibility Complex
Peptides
Neoplasms
Histocompatibility Antigens Class II
Sarcoma
Sperm Whale
Lymphocytes
Proteins
Cell Fusion
Myoglobin
COS Cells
T-Lymphocyte Subsets
Neoplasm Antigens
Immunotherapy
Immunity
Vaccines
Animal Models
Cell Line
Genes

Keywords

  • CD4 lymphocytes
  • MHC class II
  • Tumor antigens
  • Vaccination

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide. / Ladányi, A.; Nishimura, Michael I.; Rosenberg, Steven A.; Yang, James C.

In: Journal of Immunotherapy, Vol. 23, No. 1, 2000, p. 36-47.

Research output: Contribution to journalArticle

@article{5c274b70aa4e4587b94870ea355a35ad,
title = "Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide",
abstract = "The significance of CD4+ lymphocytes and major histocompatibility complex (MHC) class II-restricted antigens in antitumor immunity has been demonstrated in several animal models as well as in some human tumors. However, because of the lack of known class II-restricted antigens, the participation of CD4+ cells in antitumor responses has not been well characterized. Recent reports showed that class II proteins covalently linked to an antigenic peptide could be constructed and cells expressing these fusion proteins were recognized by specific T(H) cells. The aim of this study was to determine the effect of the expression of a class II-peptide construct on the tumorigenicity and immunogenicity of transfected murine tumor cells. We have constructed a gene for I-E(d) β chain covalently coupled to the I- E(d)-restricted T(H) cell determinant of sperm whale myoglobin (SWM132- 145). This class II fusion protein was recognized by a specific T(H) cell line on the surface of COS-7 cells or BALB/c sarcoma cells. The sarcoma cells expressing the MHC-peptide complex were rejected by immunocompetent BALB/c mice, and in vivo T-cell subset depletion experiments suggested the importance of CD4+ cells in the rejection. Moreover, splenocytes from mice immunized with tumor cells expressing the I-E(d)-SWM complex showed specific peptide recognition in vitro. Such covalent MHC-peptide complexes could prove useful in studies on the role of CD4+ lymphocytes in antitumor immune responses, and also in designing new, more effective vaccine approaches to the immunotherapy of cancer, as class II-restricted tumor-associated antigens are identified for human cancers.",
keywords = "CD4 lymphocytes, MHC class II, Tumor antigens, Vaccination",
author = "A. Lad{\'a}nyi and Nishimura, {Michael I.} and Rosenberg, {Steven A.} and Yang, {James C.}",
year = "2000",
doi = "10.1097/00002371-200001000-00006",
language = "English",
volume = "23",
pages = "36--47",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide

AU - Ladányi, A.

AU - Nishimura, Michael I.

AU - Rosenberg, Steven A.

AU - Yang, James C.

PY - 2000

Y1 - 2000

N2 - The significance of CD4+ lymphocytes and major histocompatibility complex (MHC) class II-restricted antigens in antitumor immunity has been demonstrated in several animal models as well as in some human tumors. However, because of the lack of known class II-restricted antigens, the participation of CD4+ cells in antitumor responses has not been well characterized. Recent reports showed that class II proteins covalently linked to an antigenic peptide could be constructed and cells expressing these fusion proteins were recognized by specific T(H) cells. The aim of this study was to determine the effect of the expression of a class II-peptide construct on the tumorigenicity and immunogenicity of transfected murine tumor cells. We have constructed a gene for I-E(d) β chain covalently coupled to the I- E(d)-restricted T(H) cell determinant of sperm whale myoglobin (SWM132- 145). This class II fusion protein was recognized by a specific T(H) cell line on the surface of COS-7 cells or BALB/c sarcoma cells. The sarcoma cells expressing the MHC-peptide complex were rejected by immunocompetent BALB/c mice, and in vivo T-cell subset depletion experiments suggested the importance of CD4+ cells in the rejection. Moreover, splenocytes from mice immunized with tumor cells expressing the I-E(d)-SWM complex showed specific peptide recognition in vitro. Such covalent MHC-peptide complexes could prove useful in studies on the role of CD4+ lymphocytes in antitumor immune responses, and also in designing new, more effective vaccine approaches to the immunotherapy of cancer, as class II-restricted tumor-associated antigens are identified for human cancers.

AB - The significance of CD4+ lymphocytes and major histocompatibility complex (MHC) class II-restricted antigens in antitumor immunity has been demonstrated in several animal models as well as in some human tumors. However, because of the lack of known class II-restricted antigens, the participation of CD4+ cells in antitumor responses has not been well characterized. Recent reports showed that class II proteins covalently linked to an antigenic peptide could be constructed and cells expressing these fusion proteins were recognized by specific T(H) cells. The aim of this study was to determine the effect of the expression of a class II-peptide construct on the tumorigenicity and immunogenicity of transfected murine tumor cells. We have constructed a gene for I-E(d) β chain covalently coupled to the I- E(d)-restricted T(H) cell determinant of sperm whale myoglobin (SWM132- 145). This class II fusion protein was recognized by a specific T(H) cell line on the surface of COS-7 cells or BALB/c sarcoma cells. The sarcoma cells expressing the MHC-peptide complex were rejected by immunocompetent BALB/c mice, and in vivo T-cell subset depletion experiments suggested the importance of CD4+ cells in the rejection. Moreover, splenocytes from mice immunized with tumor cells expressing the I-E(d)-SWM complex showed specific peptide recognition in vitro. Such covalent MHC-peptide complexes could prove useful in studies on the role of CD4+ lymphocytes in antitumor immune responses, and also in designing new, more effective vaccine approaches to the immunotherapy of cancer, as class II-restricted tumor-associated antigens are identified for human cancers.

KW - CD4 lymphocytes

KW - MHC class II

KW - Tumor antigens

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=0342470419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342470419&partnerID=8YFLogxK

U2 - 10.1097/00002371-200001000-00006

DO - 10.1097/00002371-200001000-00006

M3 - Article

C2 - 10687136

AN - SCOPUS:0342470419

VL - 23

SP - 36

EP - 47

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -